Neuralink, the brain-technology company co-founded by Elon Musk, has announced the launch of the PRIME Study, a clinical trial for its fully implantable, wireless brain-computer interface (BCI).
It's best suited "for those interested in developing skills in generative AI, robotics or computer vision" who want to ...
On Tuesday, Nvidia revealed its new Jetson Orin Nano Super Developer Kit, which can perform almost two times higher than its predecessor, the Jetson Orin Nano Kit from 2022, and has 50 percent more ...
Chinese researchers are planning a major clinical trial next year on technology linking ... government social media account. The brain-computer interface (BCI) technology was developed in China ...
Dec 16 (Reuters) - Merck (MRK.N), opens new tab said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials. The pharmaceutical giant ...
Stein that they had discovered that some factual information that the judge had ruled should be excluded from several trial exhibits was instead inadvertently loaded onto a computer used by jurors ...
As it faces the need to advance its network components to deliver on the promises of artificial intelligence (AI), operator Verizon has revealed the results of coherent optical network technology ...
telecoms and digital services provider Du has successfully carried out a transport network slicing trial. Operating since 2006 with a stated mission “to add life to life”, the operator offers ...
You’ve reached your account maximum for followed topics. Diablo 4 offers a free trial of the Spiritborn class from December 19 to January 3, 2025. Spiritborn is a versatile warrior with unique ...
Neuralink is conducting its PRIME study, aimed at evaluating the safety of its wireless brain-computer interface and ... study from the ongoing PRIME trial, it said in a post on social media ...
The killer, a Tren de Aragua gang member, had waived his right to a jury trial and did not testify in his own defense. This live blog has ended.